MCM
INO icon

Murphy Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Murphy Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,367
Closed -$133K – 303
2015
Q2 		$133K Buy
1,367
+392
+40% +$41.9K 0.02% 307
2015
Q1 		$95K Buy
+975
New +$94.5K 0.01% 319

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Murphy Capital Management's INO Position: Q3 2015 in Review

Murphy Capital Management sold out of Inovio Pharmaceuticals (INO) in Q3 2015, closing a stake of 1,367 shares — an estimated $133K sold.

Murphy Capital Management first reported a position in INO in Q1 2015 and held it in 2 quarters. The position peaked at $133K in Q2 2015. 114 funds tracked by Wall St. Rank hold INO as of Q3 2015.

  • Murphy Capital Management reported no remaining Inovio Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Murphy Capital Management sold 1,367 Inovio Pharmaceuticals shares in Q3 2015, an estimated $133K.
  • Murphy Capital Management first reported a position in Inovio Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Murphy Capital Management's Inovio Pharmaceuticals position peaked at $133K in Q2 2015.
  • 114 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2015.

Based on Murphy Capital Management's 13F filing for Q3 2015, filed 14 Oct 2015.